Journal: Transfusion Medicine and Hemotherapy
Submission Deadline: October 31, 2025
Mesenchymal stromal cells (MSCs) are among the most studied cell types for cellular therapy, based on the multi-faceted mechanisms of action. These range from multipotent differentiation to secretion of bioactive factors that act beneficially on the target tissue, stimulating tissue repair and modulating immune responses amongst others. However, despite the numerous promising results in preclinical studies, translation runs into the valley of death: therapeutic benefits of MSCs are not as satisfactory in clinical trial settings as they appear in preclinical models.
The bench-to-bedside-and-back approach and careful evaluation of discrepancies between preclinical and clinical results have provided valuable insights into critical components of MSC manufacturing, their mechanisms of action, and how to evaluate and quality-control them. The secreted factors are more and more coming into focus, showing a possible path to cell-free applications. Extracellular vesicles, for instance, are intensely investigated. Based on the rapidly increasing box of gene-editing tools, this is also a highly investigated topic to boost and personalize MSC-based therapies.
For an Article Collection on MSC, we welcome submissions of research and review articles as well as case reports on all aspects of MSC therapy.
Please select the option “Call for Papers: Mesenchymal Stromal Cells – From Bench to Bedside and Back” when submitting your manuscript and mention this Call for Papers in your cover letter.
Karger has established agreements with consortia and institutions that include full or partial coverage of Article Processing Charges (APC). Corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities/institutions.
Check out the Author Guidelines.